Eagle Pharmaceuticals Announces That Teva Pharmaceutical Industries Limited Requests A Motion To Dismiss With Prejudice In Its Bendamustine Patent Infringement Lawsuit

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Cephalon, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., has moved to dismiss with prejudice its first lawsuit alleging that Eagle’s tentatively approved bendamustine hydrochloride injection infusion product infringes one of its patents, U.S. Patent No. 8,445,524. The case was filed in the United States District Court for the District of Delaware in October, 2013.

“We are pleased that this case is likely to resolve satisfactorily in the near future. This recent development begins to pave the way for the launch of our product,” said Scott Tarriff, President and Chief Executive Officer.

Help employers find you! Check out all the jobs and post your resume.

Back to news